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Translation, but not transfection 
limits clinically relevant, exogenous 
mRNA based induction of alpha-4 
integrin expression on human 
mesenchymal stem cells
Adam Nowakowski1, Anna Andrzejewska1, Johannes Boltze2,3,4,5, Franziska Nitzsche2,3,  
Li-li Cui6, Jukka Jolkkonen6,7, Piotr Walczak8,9,10, Barbara Lukomska1 & Miroslaw Janowski1,8,9
Mesenchymal stem cells (MSCs) represent promising resource of cells for regenerative medicine in 
neurological disorders. However, efficient and minimally invasive methods of MSCs delivery to the 
brain still have to be developed. Intra-arterial route is very promising, but MSCs are missing machinery 
for diapedesis through blood-brain barrier. Thus, here we have tested a mRNA-based method to 
induce transient expression of ITGA4, an adhesion molecule actively involved in cell extravasation. 
We observed that transfection with an ITGA4-mRNA construct bearing a conventional cap analogue 
(7-methylguanosine) failed to produce ITGA4 protein, but exogenous ITGA4-mRNA was detected 
in transfected MSCs. This indicates that not transfection, but rather translation being the major 
roadblock. Stabilization of ITGA4-mRNA with SSB proteins resulted in ITGA4 protein synthesis in 
HEK293 cells only, whereas in MSCs, satisfactory results were obtained only after using an anti-reverse-
cap-analogue (ARCA). The presence of ITGA4 protein in MSCs was transient and lasted for up to 24 h 
after transfection. Membranous location was confirmed by flow cytometry of viable non-permeabilized 
cells using anti-ITGA4 antibody. The mRNA-based expression of itga4 transgene is potentially sufficient 
for diapedesis after intra-arterial delivery. To conclude, mRNA-based engineering of stem cells is a rapid 
and integration-free method and attractive from the perspective of potential future clinical application.
There is a growing demand for regenerative medicine solutions allowing repair or even replacement of strained 
or injured tissues, particularly as societies are ageing. Progress in this field including cell therapy and tissue engi-
neering is remarkable, but neurological diseases pose a special problem for regenerative medicine. Unlike for 
most other organs, the unique role and function of the central nervous system (CNS) makes organ transplanta-
tion unfeasible. Moreover, tissue replacement strategies are hampered by the CNS complexity1 while the previous 
failure of drug-based neuroprotection adds to the grim prognosis2. Due to its high frequency and severe sequel 
such as long-term disability, stroke results in an enormous social and financial burden to societies. Cell therapies 
are among the most promising options for stroke which can be applied beyond the extremely narrow therapeutic 
time window offered by thrombolysis. Hence, translation of experimental cell transplantation approaches into 
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clinically applicable therapies is a currently ongoing process3. The relative abundance, safety as well as easy access 
to autogenic sources make mesenchymal stem cells (MSCs) a very good candidates for use in regenerative strat-
egies4. There are many reports indicating that the application of exogenous MSCs brings beneficial therapeutic 
effects in neurological disorders5 and other ailments such as diabetes type I6, haematological7, liver8, and cardiac 
diseases9, validated by clinical trials reporting preliminary evidence for favourable outcomes10, 11. The beneficial 
results are thought to be due to trophic and immunomodulatory effects exerted by the plethora of biologically 
active compounds produced by MSCs12.
There are several potential routes to target MSCs to the ischemic brain regions including intracerebral13, intra-
ventricular14, intravenous15 and intraarterial16–18. The first two routes require craniotomy and direct puncture of 
brain parenchyma. On the other hand, the intravenous route is highly unspecific as it distributes cells throughout 
the circulation, thus requiring large doses of cells, as well as risk of side effects related to target accumulation of 
injected cells with pulmonary embolism being a prominent example19. Nevertheless, systemic delivery of ther-
apeutic MSCs seems to be a minimally invasive not only for neurological purposes (especially an intra-arterial 
route) but also for relatively “hard-to-reach” organs such as the pancreas i.e. in diabetes type I20 and pancreatic 
cancer21. Its widespread applicability is anticipated once the some obstacles constituted by the inefficient vascu-
lar extravasation of naïve MSCs in the target region is solved. First, insufficient extravasation limits the number 
of MSCs available at the lesion site. Second, size of these cells exceeds that of capillaries and their intra-arterial 
injection introduces a risk of micro-occlusions and ischemia by entrapment in the vessel lumen22, 23. This may 
severely compromise the consistent therapeutic benefits exerted by MSCs as shown in numerous animal models 
of stroke24.
Hence, diapedesis fostering fast clearance through transendothelial extravasation is of utmost importance. 
Furthermore, DNA-based genetic engineering of glial restricted precursors (GRPs) toward the expression of 
VLA-4, physiologically involved in leukocyte extravasation25 was sufficient to dock GRPs to the vessel wall26. The 
improvement of migratory properties of MSCs including extravasation can be effectively accomplished by genetic 
engineering such as overexpression of epidermal growth factor receptor using viral vector27. However, viral vec-
tors are linked to significant safety concerns and despite high transfection efficiency, they are unlikely to find wide 
clinical use28. Additionally, long-lasting transgene expression extending beyond the time required for crossing 
vascular walls is undesirable. For this purpose, safer, transient and thereby clinically more acceptable methods for 
MSC engineering are highly desired. Several examples of pDNA-based MSC modifications exist29–32. However, 
these methods do not yield high transfection efficiency.
Naïve MSCs were shown to express integrin β1 subunit (ITGB-1) but do not express the integrin α4 (ITGA4) 
subunit which is required to produce the complete VLA-4 heterodimer33. Previously, it was shown that itga4 gene 
overexpression in MSCs using viral vector led to proper routing of the protein, physiological interactions with the 
endogenous ITGB-1 subunit and assembling of functional VLA-4 heterodimers34. Thus, we decided to follow this 
strategy and engineer MSCs to overexpress the itga4 gene. Since viral-based methods have unfavourable safety 
profiles and DNA transfection is inefficient, we decided to utilize mRNA which was shown as an effective tool 
for genetic cell engineering35, 36. Since mRNA transfection is an integration-free method, inducing short-lasting 
expression and high transfection efficiency, it is ideal for the targeted transient induction of itga4 gene expression 
in MSCs. The overview of the article is presented in Supplementary Figure 1.
Results
DNA Plasmid transfection. Transfection with pITGA4(IRES)eGFP plasmid resulted in no detection of 
ITGA4 protein in MSCs (0%), while ITGA4 protein was present in 7.2% of HEK293 cells (p < 0.05) (Fig. 1A). 
The production of ITGA4 protein by HEK293 cells allowed us to confirm the proper vector design so the pro-
duced protein is detectable by immunohistochemistry. In order to clarify whether the failure of pITGA4(IRES)
eGFP plasmid expression in MSCs was due to the large construct size, we performed a transfection with smaller 
p-eGFP-N1 plasmid coding solely eGFP protein, and we also did not find any presence of eGFP protein in MSCs 
(0%), while the eGFP protein was present in 12.6% of HEK293 cells (Fig. 1B). Expectedly, we found the higher 
expression of smaller p-eGFP-N1 plasmid than larger pITGA4(IRES)eGFP plasmid in HEK293 cells (p < 0.05), 
while no expression of both plasmids was found in MSCs (Fig. 1C).
To investigate the reason for the lack of plasmid DNA expression in MSCs, we assessed whether the pIT-
GA4(IRES)eGFP plasmid was effectively internalized by the MSCs. Cell lysates were tested by PCR with prim-
ers detecting pITGA4(IRES)eGFP plasmid DNA 24 h after transfection. Its presence in the cells was confirmed 
(Fig. 1D). Nevertheless, detection of ITGA4-mRNA revealed only basal endogenous ITGA4-mRNA with indis-
tinguishable differences in mRNA levels in transfected and naïve MSCs at 24 and 48 h after transfection (Fig. 1E). 
This indicates that not transfection itself, but transcription is the major roadblock to achieve efficient protein 
production in DNA transfected MSCs.
eGFP mRNA Transfection. In contrast to DNA-based transfections, after eGFP-mRNA (Stemgent) deliv-
ery, we observed both eGFP protein positive HEK293 and MSCs. In particular, we found higher number of eGFP 
protein positive HEK293 cells using Stemfect™ (Stemgent) transfection agent (87%), than Lipofectamine®2000 
(Invitrogen) (67%) (p < 0.05) (Fig. 2A), while no significant difference was observed in case of MSCs: Stemfect – 
97%, and Lipofectamine – 98% (p = NS) (Fig. 2B). Surprisingly, more MSCs were positive for eGFP protein than 
HEK293 cells, which was observed for both transfection agents (Fig. 2C). No difference in level of eGFP expres-
sion in MSCs between both transfection compounds was observed (Fig. 2D). Furthermore, the eGFP expression 
based on eGFP-mRNA and Lipofectamine®2000 was surprisingly long lasting in MSCs and noted up to 10 days 
(p < 0.05) (Fig. 3).
Based on these results, we designed a plasmid template containing itga4 cDNA for mRNA production in vitro 
(Suppl. Fig. 2). MSCs and HEK293 cells were transfected with ITGA4-mRNA bearing conventional cap analogue 
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(7-methylguanosine) and 8 h after transfection neither HEK293 (Suppl. Fig. 3A) nor MSCs (Suppl. Fig. 3B) were 
positive for ITGA4 protein. As in case of DNA plasmid for itga4, also mRNA for itga4 was successfully delivered 
Figure 1. Plasmid DNA-based transfections of MSCs and HEK293 cells. MSCs and HEK293 visualized 24 h 
post transfection by immunofluorescence after pITGA4(IRES)eGFP plasmid (A) and p-eGFP-N1 plasmid (B). 
Quantification of percentage of cells expressing transgenes [pITGA4(IRES)eGFP/red/, p-eGFP-N1/green/] (C). 
PCR for presence of pITGA4(IRES)eGFP plasmid in MSCs 24 h after transfection (D). PCR for presence of itga4 
mRNA in MSCs transfected with pITGA4(IRES)eGFP (E). The arrows point on PCR-product corresponding 
itga4 gene (143 bp). Error bars are box-and-whiskers plots containing the mean, quartiles (box) and minimum 
and maximum observations (whiskers). Transfection efficiencies have been calculated from three independent 
experiments. Scale bar located in the top left image: 20 µm.
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to the target cells (Fig. 4). This indicates that also not transfection itself, but translation was a major roadblock to 
achieve efficient production of ITGA4 protein in MSCs and also HEK293 cells.
Effect of SSB proteins on ITGA4-mRNA translation in MSCs. In order to achieve effective 
ITGA4-mRNA translation we investigated the use of single-stranded binding (SSB) nucleic acid proteins. The 
SSB protein was shown to interact with the ITGA4-mRNA evidenced by change in the electrophoretic migration 
pattern with retarded migration of the putative ITGA4-mRNA/SSB proteins complexes (Fig. 5). These observa-
tions prompted us to conduct MSCs and HEK293 cells transfections with ITGA4-mRNA/SSB protein complexes. 
Figure 2. mRNA-based transfections of MSCs and HEK293 cells. The eGFP-mRNA transfection of HEK293 
(A) and MSCs (B) with different transfection agents. Quantification of percentage of cells expressing transgenes 
(C). Quantification of pixel intensity in MSCs transfected with different agents (D). Green – eGFP protein. 
Error bars are box-and-whiskers plots containing the mean, quartiles (box) and minimum and maximum 
observations (whiskers). Transfection efficiencies have been calculated from three independent experiments. 
Scale bar located in the top left image: 20 µm.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 1103  | DOI:10.1038/s41598-017-01304-3
ITGA4 protein was detected 5 h after lipofection in HEK293 cells (Fig. 6A), but not in MSCs in any time point up 
to 72 hours (Fig. 6B).
Effect of ARCA 5′-cap analogue on ITGA4-mRNA MSCs transfection efficacy. To further inves-
tigate the effective method for ITGA4-mRNA translation we employed an anti-reverse cap analogue (ARCA) 
instead of conventional cap analogue (7-methylguanosine). (ARCA)-ITGA4-mRNA was efficiently produced in 
vitro, and HEK293 cells as well as MSCs were transfected subsequently. The ITGA4 protein was detected in both 
cell types. The protein distribution pattern in MSCs showed gradual transition from intracellular compartments 
(3 and 5 h) towards the outer cell membrane (8 and 24 h) (Fig. 7A), and transfection efficiency was calculated 
to be around 75,1 +/− SD 14,6% (construed as whole ITGA4 positive MSCs regardless of the ITGA4 protein 
distribution in the cellular compartments 8 h after transfection by the immunocytochemical evaluation). The 
effective docking of ITGA4 to the membrane has been confirmed by flow cytometry using anti-ITGA4 antibody 
in living cells (Fig. 7B). After reaching the cell membrane, the cytoplasmic presence of ITGA-4 phased out with 
the signal present only in the cell membrane but not in the cytoplasm. The ITGA4 signal disappeared completely 
up to 72 hours after transfection. Detection of exogenous (ARCA)-ITGA4-mRNA in transfected MSCs confirmed 
cellular presence of this construct for up to seven days after transfection (Fig. 8) even though protein production 
lasted only up to 24 hours. It also confirms that translation might be a factor limiting efficiency of mRNA-based 
production of proteins.
Discussion
Here, we show expression of ITGA4 protein in MSCs after mRNA-based transfection. Our initial lack of success 
with plasmid DNA-based methods is in line with experience of others31, 37. Transfection efficiency inversely cor-
relates with plasmid size38. However, with the experiment using small size 4.7 kb p-eGFP-N1 vector we limited 
Figure 3. Time-course eGFP protein synthesis after mRNA transfection in MSCs. Time-course of eGFP 
protein presence in MSCs after eGFP-mRNA transfection on intravital fluorescent images (A) with subsequent 
quantification (B). Green – eGFP protein. Error bars are box-and-whiskers plots containing the mean, quartiles 
(box) and minimum and maximum observations (whiskers). Transfection efficiencies have been calculated 
from three independent experiments. Scale bar located in the top left image: 20 µm.
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this as a cause for lack of transgene expression. Our subsequent investigations strongly suggested that the problem 
was not in transfection, taken as a delivery of genetic material into cells, but rather transcription of plasmid DNA 
into mRNA (Fig. 1). Transcription was particularly inefficient in MSCs. In the process of transfection, DNA is 
internalized and is initially degraded in lysosomes. Escaping these clearing mechanisms is required for sufficient 
Figure 4. Exogenous ITGA4-mRNA delivery to MSCs. RT-PCR of MSC lysates after ITGA4-mRNA 
transfection: The higher band refers to ITGA4-mRNA (143 bp) and lower band to housekeeping gene: GAPDH 
(73 bp).
Figure 5. SSB protein binding assay in vitro. Electrophoresis after SSB protein to ITGA4-mRNA in vitro 
binding assay: 1) 1 kb DNA ladder, 2) ITGA4-mRNA, 3) ITGA4-mRNA/SSB, 4) ITGA4-mRNA/SSB/
Lipofectamine®2000, 5) SSB/Lipofectamine®2000, 6) SSB, 7) Lipofectamine®2000.
www.nature.com/scientificreports/
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cytoplasm concentration, nucleus entry and subsequent transcription39. We speculate that the process of lysoso-
mal escape is ineffective in MSCs, preventing DNA from further processing. This point, however, requires future 
investigation.
In light of these unsatisfactory results, mRNA-based transfection was developed. Ryser and colleagues 
reported that electroporation of CXCR4-mRNA resulted in over 90% positively transfected MSCs36. However, 
electroporation disintegrates cell membrane stability with potential side effects and can reduce cell viability. Thus 
it is not desired for use in cell populations directly before transplantation. Lipofectamine®2000 was found as an 
attractive transfection agent for mRNA delivery to MSCs (Figs 2 and 3), ensuring fairly high cell viability35 and 
efficient delivery40. However, genes used in these studies were smaller compared to itga4, which might explain 
why the approach was not effective in our hands although successful delivery of nucleic acid to the cells could be 
shown. Our next strategy was to stabilize exogenous mRNA with the use of SSB proteins (Fig. 5), which failed 
for MSCs (Fig. 6). Similar SSB protein utility has been described for other more naïve cell populations including 
tumor cells41. To exclude technical problems, we reproduced the result of Shi et al. in HEK293 immortalized cells. 
This result indicates profound differences in mRNA handling between tumor/immortalized cell lines and popu-
lations of primary stem cells such as MSCs, which must be taken into account.
The ITGA4 protein synthesis in transfected MSCs was finally achieved by using ARCA-modified 
ITGA4-mRNA ((ARCA)-ITGA4-mRNA) (Fig. 7). During in vitro production of mRNA the conventional cap 
analogue is incorporated in correct orientation only in 50% of cases. The design of an ARCA cap analogue guar-
antees incorporation of nucleotides exclusively in the normal/physiological orientation during in vitro synthesis. 
In consequence, it enables recognition by translation initiating proteins. This was an important innovation for 
extracellular in vitro production of functional mRNA42. It was found later that ARCA also increases translational 
efficiency and decays resistance43. The abovementioned properties may have contributed to the production of 
ITGA4 protein in MSCs, particularly through a delay of the 5′-decapping process of (ARCA)-ITGA4-mRNA 
preventing the mRNA chain from the exposure to exonuclease- mediated degradation44, 45.
Although we observed translocation of ITGA4 protein from perinuclear cytoplasm to the membrane (Fig. 7), 
the expression lasted for a relatively short period of time 24 h, which was much shorter than eGFP expression (up 
to 10 days). Since mRNA was active directly after transfection, the complete failure of release from lysosomes 
is relatively unlikely as is a potential “secondary” or delayed entrapment of mRNA in lysosomes. We hypothe-
size that eGFP is not a native protein in vertebrates, thus human MSCs may be lacking mechanisms for specific 
silencing of this mRNA. The microRNA may be postulated as such mechanism46. In both cases mRNA containing 
Figure 6. ITGA4 protein synthesis after ITGA4-mRNA/SSB transfection. Immunocytochemistry study for 
assessment of the ITGA4 protein presence after ITGA4-mRNA/SSB transfection using Lipofectamine®2000. 
Scale bars separate for HEK293 and MSC cells located in the respective left upper images of the panel indicate 
100 µm.
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specific sequence may be present in cells for some time, which is in line with our observation that transfected 
mRNA is present in cells longer than translated to proteins (Fig. 8).
Not only integrins but also selectins participate in the process of diapedesis. It was recently shown that triple 
gene engineered (including two selectin ligands), intravenously injected MSCs home more efficiently to the spinal 
Figure 7. ITGA4 protein distribution in (ARCA)-ITGA4-mRNA transfected MSCs. Time-course of ITGA4 
protein production – note its translocation from perinuclear area in 3 and 5 hour time-points toward the 
cell membrane in 8 and 24 hour time points (A). The presence of ITGA4 protein on the cell membrane was 
confirmed in living cells by flow cytometry performed 20 h after transfection (B). red – ITGA4 protein, blue – 
Hoechst 33258. Scale bar: 20 µm.
Figure 8. Longitudinal study of ITGA4-mRNA presence in transfected MSCs. RT-PCR results from MSCs 
transfected with (ARCA)-ITGA4-mRNA confirmed that delivered (ARCA)-ITGA4-mRNA was present in 
transfected cells at least for 168 h.
www.nature.com/scientificreports/
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cord of animal models what directly translates into therapeutic activity47. However, the authors were not able to 
detect transplanted cells through reporter gene assays and or the used membranous label. The co-localization of 
this marker with immune cells may indicate that MSC and/or any released label were phagocytosed. Moreover, 
the authors did not perform vessels staining such as claudin-5 so no information about diapedesis can be drawn. 
It was previously shown that intravenously injected cells should rather have blocked homing ligands to pass 
pulmonary capillaries without being filtered48. Additionally, MSCs entrapped in lungs release TSG6, what may 
decrease local inflammation49, what may explain therapeutic efficacy without cell detection in situ in this par-
ticular study. Three mRNAs can be more cumbersome to apply, and less attractive from clinical perspective than 
using only one mRNA, as in our case.
While long-lasting expression of a transgene may be sought in many applications, in our case the feature of 
short-term expression may exactly fit requirements. Diapedesis is a fast process50, while extended expression of 
the homing receptors in turn might cause safety concerns rather than providing enhanced therapeutic efficacy. 
In a hypothetical clinical scenario, the provided MSCs (just thawed or maintained in culture in vitro) can be 
transfected overnight, with most of the cells effectively engineered (no need for sorting as in case of DNA) and 
transplanted to the patient without major delays. Thus, mRNA-based engineering is a very convenient tool for 
inducing short-lasting manipulations in therapeutic cells.
Concluding Remarks
In this study, we demonstrated that plasmid DNA-based transgene delivery to MSCs was ineffective, prompting 
the use of mRNA-based transfection approaches. However, mRNA based transfection strategy is related to spe-
cific problems such as exogenous mRNA stability and recognition by protein production machinery that need to 
be solved in the first instance. We further demonstrated here that not transfection but rather translation efficiency 
of exogenous mRNA seems to be the major obstacle in efficient mRNA-based engineering of MSCs. Methods that 
are efficient in inducing exogenous expression using mRNA-based transfection in tumor/immortalized cell lines 
do not necessarily apply to primary stem cells such as MSCs. The use of ARCA 5′-cap analogue resulted with suc-
cessful production of ITGA4 protein in MSCs. The possibility for overnight mRNA-based ubiquitous engineering 
of stem cells prior to transplantation is compelling.
Materials and Methods
Cell culture. Human mesenchymal stem cells (hMSCs, PT-2501, Lonza) were obtained from randomly 
selected healthy donors of both sexes with ages ranging from 19 to 38 years old and cultured in dedicated medium 
MSCBM (PT-3238) supplemented with 10% MCGS (PT-4106E), L-glutamine (PT-4107E), and gentamicin sulfate 
(GA-1000, PT-4504E, all Lonza), which was changed twice a week. Cells were maintained for up to 9 passages in 
75 cm2 plastic bottom flasks and split once a week. For transgene induction experiments, cells were transferred to 
24-well plates and seeded at a density of 1.5 × 104 cells/well. HEK293 cells served as controls and were cultivated 
in DMEM medium (31966 GlutaMAX, GIBCO) with 10% FBS (P40-37500HI, PAN™Biotech) and penicillin/
streptomycin (P11-010, PAA). Cells were grown in 25 cm2 flasks, but for transfections assays were transferred to 
24-well plates at a density of 70 × 103 cells/well. Both cell types were cultured in a humidified atmosphere at 37 °C 
and 5% CO2.
Genetic material. Plasmid vectors. A p-eGFP-N1 vector containing the enhanced green fluorescence pro-
tein (eGFP) gene was purchased from BD Biosciences (PT 3027-5, BD). A commercially designed vector for 
mRNA synthesis in vitro (2.4 kbp pSP72 plasmid) was obtained from Promega (P2191, Promega). pITGA4 and 
pITGA4(IRES)eGFP plasmids were produced in our lab (The Johns Hopkins University School of Medicine, 
Baltimore, by Dr. Walczak).
mRNA synthesis in vitro. In order to produce mRNA in vitro, a fragment containing itga4 gene cDNA was 
released from the pITGA4 vector by simultaneous XbaI (FD0684, ThermoScientific) and XhoI (FD0694, 
ThermoScientific) digestion before being cloned into the pSP72 vector with T4 DNA ligase (EL0014, 
ThermoScientific). This newly created pITGA4-SP72 vector was sequenced (ABI3730 Genetic Analyzer, Applied 
Biosystems) and used as a template for the mRNA production in vitro. The mMessage mMachine® Kit (AM1344, 
Ambion®), mMessage mMachine® T7 Ultra Kit (AM1345, Ambion®) and poly (A) tailing kit (AM1350, 
Ambion®) were used according to the manufacturers’ instructions. Synthesized mRNA was precipitated by LiCl 
and washed with 70% EtOH, and mRNA concentration was evaluated spectroscopically (NanoDrop®ND-1000, 
ThermoScientific). Control eGFP-mRNA (100 ng/µl) was purchased (05-0020, Stemgent).
Single-Strand Binding Protein assay in vitro. Single-Strand Binding Protein (SSB) was delivered from Sigma 
(S3917, Sigma). For in vitro RNA/SSB complex formation assays, 0.25 µg of ITGA4-mRNA was incubated with 
10 µg of SSB protein with or without 1 µl of Lipofectamine® 2000 (11668-019, Life Technologies) in Opti-Mem® 
I (1x) Reduced Serum Medium (31985-047, Life Technologies; final volume: 12 µl) for 20 minutes at RT. Then, 
1% agarose gel electrophoresis was performed in non-denaturing conditions. 1 kb Plus DNA Ladder (10787-018, 
Invitrogen) was used as a DNA size marker.
Preparation of transfection complex and cells transfections with Lipofectamine® 2000. 24 h prior to trans-
fection, MSCs and HEK293 cells were plated on coverslips previously treated with poly-L-lysine 40 µg/ml 
(P2636, Sigma). Growing medium was removed 30 minutes before transfection, cells were washed with PBS, 
and 200 µl of Opti-Mem® I (1x) Reduced Serum Medium (31985-047, Life Technologies) was poured per well. 
48 µl of Opti-Mem® I (1x) Reduced Serum Medium were prepared in a 1.5 ml sterile plastic tube and 2 µl of 
Lipofectamine® 2000 (Invitrogen) were added, followed by 5 minutes incubation at room temperature (RT). 
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Meanwhile, 0.12–0.5 µg mRNA or 1.0 µg plasmid DNA was diluted with 50 µl of Opti-Mem® I (1x) Reduced 
Serum Medium. Controlled cells were processed with the same protocol, but in mRNA-free manner. In vari-
ants where SSB protein was used for mRNA stabilization, 0.25 µg of ITGA4-mRNA and 10 µg of SSB protein 
were applied for the lipoplex formation. Liposome reagent and genetic material samples were mixed for lipoplex 
formation and incubated for 20 minutes at RT. In the next step, 100 µl of the reaction mix was administrated to 
the cells followed by 4 h incubation at 37 °C/5% CO2. Lipoplex containing medium was removed afterwards and 
standard growing medium was added.
Stemfect™RNA Transfection Kit. Stemfect™RNA Transfection Kit was purchased from Stemgent (00-0069, 
Stemgent). For transfection, mRNA was diluted with Stemfect Transfection Buffer in total volume of 11.5 µl in a 
1.5 ml sterile tube. In a separate tube, 2 µl of Stemfect RNA Transfection Reagent were added to 12.5 µl of Stemfect 
Transfection Buffer. The contents of these two tubes were mixed and incubated for 10 minutes at RT, followed by 
drop-let administration to the cells residing in 500 µl of standard growing medium. That growing medium was 
changed 24 h post transfection.
PCR and RT-PCR. For PCR and RT-PCR analysis respectively, cells were collected at 8, 24, 48, 72, 96, 120, 
144 and 168 h after transfection, washed with PBS and lysed with TRIzol® Reagent (Ambion®). RNA and plas-
mid DNA samples were obtained by chloroform extraction, followed by precipitation with isopropanol and 
purification with 75% EtOH. Samples were air-dried and dissolved in RNase-free water. RNA samples were 
DNase-treated (DNA-free™ Kit AM1906, Ambion®) and RNA concentration was measured using the NanoDrop 
technology (NanoDrop®ND-1000, ThermoScientific). High-Capacity RNA-to-cDNA™ Kit (4387406, Applied 
Biosystems®) was used according to the manufacturer’s instructions for Reverse Transcription reactions. For 
PCR amplifications Taq DNA Polymerase (201205, Qiagen) was employed with the following pairs of primers.
ITGA4-forward: 5′-ACAGATGCAGGATCGGAAAG-3′
ITGA4-reverse: 5′-CCTGGCTGTCTGGAAAGTGT-3′,
GAPDH-forward: 5′-CCACATCGCTCAGACACCAT-3′,
GAPDH-reverse: 5′-TGACCAGGCGCCCAATA-3′.
PCRs were carried out in total volume of 10 µl as follows: initial denaturation for 3 min at 97 °C, followed by 25 
cycles (30 sec at 97 °C, 30 sec at 60.3 °C, 45 sec at 72 °C), and final elongation step for 10 min at 72 °C. Subsequent 
electrophoresis was performed in 2% agarose gels (basica le cgt, Prona) in TAE1x buffer and photos were taken 
by G:box (Syngene).
Immunocytochemistry assays. For immunocytochemistry assays, transfected and control cells were incu-
bated for 3, 5, 8, 24 and 72 h after transfection in a humidified atmosphere at 37 °C and 5% CO2. Cells were 
then fixed with PFA 4% (Roth)/PBS for 10 minutes, followed by permeabilization with 0.3% TritonX (Triton® 
X-100 Sigma Ultra T9284, Sigma)/PBS for 5 minutes. Samples were blocked with 5% BSA (A9647, Sigma)/PBS 
and incubated with primary antibody (mouse-monoclonal-IgG1 anti-ITGA4 (MAB1354, RD) diluted 1:200 in 
0.2% BSA/PBS) solution overnight at 4 °C. After washing with PBS, cells were incubated with goat-anti-mouse 
IgG(H + L)-AlexaFluor488 (A11001, Invitrogen) for 1 h. Hoechst 33258 (B-2883, Sigma) or DAPI were used 
as a counterstains. Samples were examined using a Zeiss AX10 microscope and micrographs were analyzed by 
ZEN (blue edition) software (Carl Zeiss MicroImaging GmbH). In quantitative examinations, at least 1000 cells 
were counted per each individual experiment or ten randomly selected microscopic fields were selected at x20 
or x40 magnification and expressed as a percent of fluorescent cells among all of cells. In the particular case of 
pITGA4(IRES)eGFP transfection, only ITGA4-positive cells were classified as positive. If no difference in the 
percent of positive cells was found, the level of gene expression was investigated additionally in order to select the 
best transfection factor for further experiments. This was done by the measurement of pixel intensity per image 
with at least 8 images per group were used for quantification.
Flow cytometry analysis. Prior to the respective experiment, control and transfected MSCs were cultivated in 
25 cm2 flasks. Cells were detached by trypsinization, and resuspended in 2 mM EDTA/0.3% BSA/PBS solution. In 
the next step, cells were labeled using the following antibodies: APC Mouse IgG1, κ Isotype Control (555751, BD 
Pharmingen™), PE Mouse IgG1, κ Isotype Control (555749, BD Pharmingen™), APC Mouse Anti-Human CD29 
(559883, BD Pharmingen™), PE Mouse Anti-Human CD49d (555503, BD Pharmingen™), washed and analyzed 
by BD FACSCanto II (BD Bioscences).
Statistics. Restricted maximum likelihood approach (PROC MIXED, SAS 9.4) has been used to determine sta-
tistical significance which was considered at p < 0.05.
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